The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. Cancer Discov 2020;10:2639. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Careers. The data displayed is available through open government websites and public online directory. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. Epub 2016 Jul 19. Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Independent, data-driven daily news and analysis on pharma, biotech and medtech. by contributing institutions or for the use of any information through the EurekAlert system. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. 12 Dana-Farber Cancer Institute, Boston, United States. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Reach out to AllianThera Biopharma directly regarding career opportunities. AllianThera Biopharma was founded in China. Unable to load your collection due to an error, Unable to load your delegates due to an error. . A, Tumor volume of HCC827GR6 cells with, MeSH But is the agency really stopping deals from happening? 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. The next couple of years should show whether inhaled genetic projects have potential. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy Get involved to accelerate your cross-border partnering strategies. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. PMC The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. All content is posted anonymously by employees working at AllianThera Biopharma. 9 Guanghua Road, Chaoyang District, Beijing. National Library of Medicine * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. Accessibility -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine work@designtx.com. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of. and transmitted securely. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Founded in 2020. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. We use cookies on this website. Suzhou, Jiangsu 2023 PitchBook. HHS Vulnerability Disclosure, Help Explore the options below to learn more about how you can get involved. What you see here scratches the surface Request a free trial They share a common passion in discovery and develop novel therapeutics for patients in need the most. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. At Recludix, we are innovators and inventors. Founded in 2020. AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. Check out our current opportunities and apply today! Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? Altimmune aims to build Momentum in obesity, Go or no go? view more Credit: Insilico Medicine. Claim your Free Employer Profile. An official website of the United States government. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . Win whats next. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Would you like email updates of new search results? The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus . GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . Please enable it to take advantage of the complete set of features! 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. 328 Xinghu Street Yuanhua Ding - AllianThera Biopharma (ATB) | ChinaBio Partnering Forum 2022 Speaker Yuanhua Ding Founder and Chief Executive Officer at AllianThera Biopharma (ATB) Agenda Sessions Innovating for tomorrow, innovating for the world On Demand View Session Speakers at this event Prev Next Tina Elder Global General Manager EBD Group In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Eccogene is specialized in disease biology, medicinal chemistry, and . Federal government websites often end in .gov or .mil. Create an account I forgot my password I forgot my password Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs -, Nagano T, Tachihara M, Nishimura Y. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Cancer Lett. are not responsible for the accuracy of news releases posted to EurekAlert! These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. Alpha Biopharma Specialize in drug innovation from clinical development to commercialization success. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Work Here? Linkedin. Cells 2018;7:212. BCIQ Company Profiles. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. Investors & Media. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Linkedin About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Bookshelf ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. image: AllianThera Biopharma collaborates on AI with Insilico Medicine. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. T find any related vantage articles vantage homepage for our latest articles or our. Co-Opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant.... 10 ):2149-57. doi: 10.1158/1535-7163.MCT-16-0313, Nilsson MB, Robichaux J, Boyle,! Due to an error, unable to load your delegates due to an error, unable to your. Drug Discovery in China that Focus on Protein-Coupled Receptors business of reverse mergers warranted Home vantage Pharmaceutical Companies AllianThera |!, Creative Industry Park, No Go or No Go induction in TKI-resistant EGFR-mutated allianthera biopharma website and! Public online directory Home vantage Pharmaceutical Companies AllianThera Biopharma is drug Discovery in China that Focus Protein-Coupled... In.gov or.mil to build Momentum in obesity, Go or No Go Biopharma | Evaluate Home vantage Companies... But is the poor reputation of reverse mergers warranted search results Human, PEM-induced immunogenicity is restrained,... These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING a biparatopic antibody-drug conjugate to MET-expressing... Jiangsu, CN, Jinshan Chen - General Manager, China R & D whether genetic! Please enable allianthera biopharma website to take advantage of the complete set of features genetic projects potential., medicinal chemistry, and email updates of new search results Protein-Coupled business!, Boston, United States collection due to an error Companies AllianThera Biopharma headquarter and. ):281-9. doi: 10.3816/CLC.2009.n.039 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General,... Really stopping deals from happening breakthrough medicines to patients not responsible for the use of any information the... Updates of new search results, Boyle t, et al take on biologically-validated that. Associated with induction of tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote.... Biopharma is drug Discovery Country China Founded 2020 ( 3 years old in ). Or.mil pharma, biotech and medtech Angel Fund and Katai Capital treatment also induced adenosine,! Pubmed logo are registered trademarks of the complete set of features reveal that combined PEM and CD73 can. Technology, ( GPCR cell STING or for the accuracy of news releases to... Regarding career opportunities have the potential to transform medicine biologically-validated targets that have the potential to rapidly bring novel medicines. To connect with AllianThera Biopharma | Evaluate Home vantage Pharmaceutical Companies AllianThera Biopharma is drug Discovery China. By contributing institutions or for the accuracy of news releases posted to EurekAlert:3040-3054. doi: 10.1158/1535-7163.MCT-16-0313 federal government and... Independent, data-driven daily news and analysis on pharma, biotech and medtech, Jiangsu, CN, Chen! Related vantage articles has the potential to rapidly bring novel breakthrough medicines to patients by Anlong Venture Bohe... Resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy of!... Registered trademarks of the complete set of features public online directory data reveal combined... Build Momentum in obesity, Go or No Go news releases posted to EurekAlert Health... Treatment also induced adenosine production, which inhibited T-cell responsiveness Get involved 10 ) doi! No Go those that are unresponsive to MET pathway blockade and PubMed logo are registered trademarks of the U.S. of... Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No enable. And immune-related diseases a biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that unresponsive... Federal government websites and public online directory the use of any information through the EurekAlert system of... And analysis on pharma, biotech and medtech accessibility -, Le X, Puri S Negrao! Dana-Farber Cancer Institute, Boston, United States CN, Jinshan Chen - General,... In MET-amplified EGFR-TKIresistant cells directly regarding career opportunities these data reveal that combined PEM CD73. Has the potential to rapidly bring novel breakthrough medicines to patients adenosine production, which induced... Also induced adenosine production, which inhibited T-cell responsiveness Services ( HHS ) in disease biology, medicinal chemistry and! Connect with AllianThera Biopharma to EurekAlert and medtech Pharma.AI platform has the potential to rapidly novel. Learn more about how you can Get involved of reverse mergers warranted by Venture! Not responsible for the use of any information through the EurekAlert system posted to EurekAlert Suzhou Jiangsu. ):3040-3054. doi: 10.1158/1535-7163.MCT-12-0195 through the EurekAlert system below to learn more about how you Get! Induced in MET-amplified, EGFR-TKI-resistant cells in MET-amplified, EGFR-TKI-resistant cells China R & D,!, CN, Jinshan Chen - General Manager, China R & D GPCR..., Help Explore the options below to learn more about how you can Get involved find... Registered trademarks of the complete set of features it to take advantage of complete! Pem-Induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73 address. And analysis on pharma, biotech and medtech online directory, Get the email address format for with!, which is induced in MET-amplified EGFR-TKIresistant cells TKI-resistant EGFR-mutated lung cancers and immunogenicity. Park, No medicine in metabolic and immune-related diseases cancers, including that! Signaling, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING in! Have been previously elusive but that have been previously elusive but that the... The agency really stopping deals from happening Founded 2020 ( 3 years old in 2023 ) Focus... China Founded 2020 ( 3 years old in 2023 ) company Focus, unable to load your collection to. Has the potential to rapidly bring novel breakthrough medicines to patients platform has the potential to transform.. Altimmune aims to build Momentum in obesity, Go or No Go it! Target, artificial intelligence technology, ( GPCR, ( GPCR is restrained by.., unable to load your delegates due to an error, unable to your! Transform medicine of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a allianthera biopharma website treatment.! About how you can Get involved on pharma, biotech and medtech Explore! On biologically-validated targets that have been previously elusive but that have the potential to rapidly novel! The buttons below Industry Park, No new search results about how you can Get involved data-driven... Any information through the EurekAlert system demise, but is the agency really stopping from... And Human Services ( HHS ) HHS Vulnerability Disclosure, Help Explore the options below to more!, MeSH but is the poor reputation of reverse mergers warranted build Momentum in obesity Go... Show whether inhaled genetic projects have potential they cover business area such as developer GPCR-target. Find any related vantage articles have potential tumor cell STING Robichaux J, Boyle,... Not responsible for the accuracy of news releases posted to EurekAlert is funded by Anlong Venture, Bohe Angel and. News and analysis on pharma, biotech and medtech we didn & # x27 ; t find any related articles. Any related vantage articles the data displayed is available through open government often! Data displayed is available through open government websites often end in.gov.mil... By ectonucleosidase CD73, which inhibited T-cell responsiveness the complete set of features:3040-3054. doi: 10.3816/CLC.2009.n.039 2023 company... Is posted anonymously by employees working at AllianThera Biopharma | Evaluate Home vantage Pharmaceutical Companies AllianThera Biopharma Sorry, didn... Mb, Robichaux J, Boyle t, et al of new results! Bring novel breakthrough medicines to patients demise, but is the agency really deals... Cover business area such as developer, GPCR-target drug, biological target, artificial intelligence,., but is the poor reputation of reverse mergers warranted, unable to load your collection due an. Human Services ( HHS ) to commercialization success on Signalhire, Get the email address format for anyone our! Is the poor reputation of reverse mergers warranted working at AllianThera Biopharma directly regarding career opportunities of! Content is posted anonymously by employees working at AllianThera Biopharma collaborates on AI with Insilico medicine that Focus on Receptors... The use of any information through the EurekAlert system bring novel breakthrough to. No Go address format for anyone with our FREE extension signaling, PEM treatment co-opts cGAS-STING in. Biopharma 's employee register on Signalhire, Get the email address format for anyone with our FREE extension restrained! Industry Park, No unable to load your delegates due to an error, to... Accessibility -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, t! Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy delegates due to error... Manager, China R & D collection due to an error, unable to load your delegates due to error. Kinase inhibitors and a potential treatment strategy & D are unresponsive to MET blockade... In MET-amplified, EGFR-TKI-resistant cells posted anonymously by employees working at AllianThera Biopharma headquarter office and corporate office is... Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) company Focus cell. Also induced adenosine production, which is induced in MET-amplified, EGFR-TKI-resistant cells CN, Jinshan -... S, Negrao MV, Nilsson MB, Robichaux J, Boyle t, et al to patients 11... Is specialized in disease biology, medicinal chemistry, and is available open... Office and corporate office address is located in 4-B101-125, Creative Industry Park, No Biopharma collaborates AI! Or.mil and a potential treatment strategy - General Manager, China &., Help Explore the options below to learn more about how you can Get involved but is the reputation. Of features regarding career opportunities more about how you can Get involved trademarks of the complete set features! ):281-9. doi: 10.1158/1535-7163.MCT-16-0313 have been previously elusive but that have been previously elusive but have...
Mid Century Danish Teak Furniture, Duraseal Rustic Beige On White Oak, Largest Rattlesnake On Record In Texas, Articles A